Hikma Pharmaceuticals (LON:HIK) Price Target Raised to GBX 2,560 at Berenberg Bank

Hikma Pharmaceuticals (LON:HIK) had its price target boosted by Berenberg Bank from GBX 2,400 ($29.88) to GBX 2,560 ($31.87) in a research report report published on Wednesday morning,Digital Look reports. They currently have a buy rating on the stock.

Hikma Pharmaceuticals Stock Up 1.4 %

Shares of HIK traded up GBX 32 ($0.40) on Wednesday, hitting GBX 2,280 ($28.39). The company’s stock had a trading volume of 1,778,026 shares, compared to its average volume of 1,237,701. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.48. The firm’s fifty day moving average price is GBX 2,001.97 and its 200-day moving average price is GBX 1,947.80. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,750 ($21.79) and a fifty-two week high of GBX 2,290 ($28.51). The firm has a market capitalization of £5.06 billion, a price-to-earnings ratio of 3,507.69, a P/E/G ratio of 2.38 and a beta of 0.41.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.